cell

(redirected from myeloma cell)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia.
Related to myeloma cell: hybridoma

cell

(Enemy combatants), noun enemy group, exxremist group, rebel organization, saboteurs, subversives, unnerground extremists
Associated concepts: enemy combatants, justice courts, miliiary tribunals, Patriotic Act, prison cells, sleeper cell, terrorist cell

cell

(jail), noun cage, cella, chamber, compartment, confined room, confinement, cubicle, cubiculum, enclosed cage, incarceration, jailhouse, penitentiary, pound, prison, prison house, small cavity, small room, solitary abode
See also: chamber, jail, penitentiary, prison

CELL. A small room in a prison. See Dungeon.

References in periodicals archive ?
A, qRT-PCR, and B, western blot analysis of the mRNA and protein levels of ALR, respectively, in U266 multiple myeloma cells and healthy peripheral blood mononuclear cells (PBMCs).
Cell fusion: Sp2/0 myeloma cells were grown in RPMI-1640 culture medium (added 10% FBS) for 4-5 d at 37degC in a 5% CO2 atmosphere.
Previous studies have shown that growth hormone and somatomedin-C activate B lymphocyte and somatomedin-C receptors are found in multiple myeloma cells.
To our knowledge, no detailed reports have so far been published regarding lipoplex and polyplex-mediated transfection of DNA into different myeloma cell lines.
Histological parameters that have a definitive prognostic significance in multiple myeloma are the percentage of myeloma cells in the marrow, pattern of infiltration, degree of plasma cell atypia, marrow fibrosis and mitotic index.
Inhibition of Aurora A has been shown to induce cell death in preclinical multiple myeloma cell lines.
DMA(V) exerted differential antiproliferative and cytotoxic activity against leukemia and multiple myeloma cells, with no significant effect on normal progenitor cells (Duzkale et al.
181 showed that uPAR expression depended on myeloma cell maturation and that immature myeloma cells had high expression levels.
The results, achieved in multiple myeloma cells, offer a promising strategy for treating not only myeloma but also many other cancer types driven by the gene MYC, according to the study authors.
Elotuzumab, an investigational immunotherapy, is a humanized monoclonal antibody that enhances immune cell mediated killing of multiple myeloma cells that have a surface protein called CS1.
Because BCMA has been shown to play a potential role in survival and growth of myeloma cells, it is viewed as an attractive CAR T-cell therapeutic target.